Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}
organic renal impairment, LBP
BLOOD
Blood and urine and optional stool samples for the central laboratory will be obtained at baseline, 3, 6, 9, and 12 months. These will be obtained in order to evaluate in further research the pathophysiological mechanisms involved in the development of HRS-AKI such as the activation of vasoactive parameters (Renin, Aldosterone, Noradrenalin) and bacterial translocation (IL-6, Endocab, LBP). An initial planned exploratory subanalysis will be performed according to blood and urine markers of functional or organic renal impairment (Cystatin C and uNGAL). Stool samples will be optionally collected for future exploratory analysis regarding the influence of the gut microbiome on outcomes. Embedded future substudies for research on HRS will have their specific protocol and will obtain specific approval from the ethic committee separately.